Skip to main content

ORTHOFIX International N V Value Stock - Dividend - Research Selection

Orthofix international n v

ISIN: US68752M1080 , WKN: A2NB0X

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Orthofix International N.V., a medical device company, provides musculoskeletal healing products and value-added services worldwide. It operates through four segments: BioStim, Extremity Fixation, Spine Fixation, and Biologics. The BioStim segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spine fractures. The Extremity Fixation segment designs, develops, and markets orthopedic products used in fracture repair, deformity correction, and bone reconstruction procedures. The Spine Fixation segment designs, develops, and markets a portfolio of implant products used in surgical procedures of the spine. The Biologics segment provides a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. Orthofix International N.V. was founded in 1987 and is headquartered in Lewisville, Texas.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Orthofix Medical Inc. (OFIX) Presents at UBS Global Healthcare Conference 2025 Transcript

2025-11-11
Orthofix Medical Inc. (OFIX) UBS Global Healthcare Conference 2025 November 11, 2025 1:15 PM ESTCompany ParticipantsMassimo Calafiore - President, CEO &...

Orthofix Medical Inc. (NASDAQ:OFIX) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

2025-11-07
Orthofix Medical Inc. ( NASDAQ:OFIX ) shareholders are probably feeling a little disappointed, since its shares fell...

Orthofix Medical (OFIX): Losses Deepen, Undervalued Stock Tests Bullish Recovery Narratives

2025-11-05
Orthofix Medical (OFIX) reported ongoing losses, with net profit margins failing to improve and losses increasing at an average annual rate of 42.7% over the past five years. Despite these challenges, revenue is expected to grow at 4.8% per year, which remains well below the broader US market’s anticipated growth of 10.5%. Investors appear cautious, but the stock is currently trading at $14.87, significantly below the estimated fair value of $25.85 and at a price-to-sales ratio of just 0.7x...

Orthofix Medical Inc (OFIX) Q3 2025 Earnings Call Highlights: Strong Growth in US Spine and ...

2025-11-04
Orthofix Medical Inc (OFIX) reports robust revenue growth and continued EBITDA margin expansion, while navigating pricing pressures and distributor transitions.

Orthofix (OFIX) Beats Q3 Earnings and Revenue Estimates

2025-11-04
Orthofix (OFIX) delivered earnings and revenue surprises of +66.67% and +2.65%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Orthofix: Q3 Earnings Snapshot

2025-11-04
LEWISVILLE, Texas (AP) — Orthofix Medical Inc. OFIX) on Tuesday reported a loss of $22.8 million in its third quarter. On a per-share basis, the Lewisville, Texas-based company said it had a loss of 57 cents.

Orthofix Reports Third Quarter 2025 Financial Results

2025-11-04
LEWISVILLE, Texas, November 04, 2025--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2025, narrowed its full-year 2025 net sales guidance while maintaining the midpoint, and raised the low end of its adjusted EBITDA guidance. All pro forma measures contained within this release exclude the impact of the Company’s decision to discontinue its M6™ product lines.

Orthofix Medical Inc. (OFIX) Q3 2025 Earnings Call Transcript

2025-11-04
Orthofix Medical Inc. (OFIX) Q3 2025 Earnings Call November 4, 2025 8:30 AM ESTCompany ParticipantsJulie Dewey - Chief Investor Relations &...

Orthofix Medical Inc. (OFIX) Q3 2025 Earnings Call Prepared Remarks Transcript

2025-11-04
Orthofix Medical Inc. (OFIX) Q3 2025 Earnings Call November 4, 2025 8:30 AM ESTCompany ParticipantsJulie Dewey - Chief Investor Relations &...

Orthofix Medical Inc. 2025 Q3 - Results - Earnings Call Presentation

2025-11-04
2025-11-04. The following slide deck was published by Orthofix Medical Inc.